Search

Your search keyword '"Simona Scodes"' showing total 8 results
Start Over Author "Simona Scodes"
8 results on '"Simona Scodes"'

1. The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer

Author

Giuseppe Bronte, Maurizio Puccetti, Elisabetta Petracci, Lorenza Landi, Paola Cravero, Simona Scodes, Paola Ulivi, Sara Ravaioli, Maria Maddalena Tumedei, Marco Angelo Burgio, Federico Cappuzzo, Angelo Delmonte, Lucio Crinò, and Sara Bravaccini

Subjects
vimentin, programmed death ligand 1, non-small-cell lung cancer, epithelial-to-mesenchymal transition, immunohistochemistry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

BackgroundCurrent therapy for non-small-cell lung cancer (NSCLC) frequently includes immune checkpoint inhibitors, such as pembrolizumab, and programmed death ligand 1 (PD-L1) positivity is mandatory for its use in this setting. Vimentin plays a role in carcinogenesis through the activation of the epithelial-to-mesenchymal transition (EMT) process. Its prognostic impact in NSCLC has been investigated in numerous studies but little data are available on its relation with PD-L1 expression.Patients and MethodsWe retrospectively retrieved data on patients with advanced NSCLC consecutively enrolled in a clinical trial at our institute. PD-L1 and vimentin expression were determined by immunohistochemistry. Correlations between variables were assessed using the Spearman correlation coefficient. The Kaplan-Meier method was used to estimate overall survival (OS) and the Log-rank test was used to compare survival curves. The association between demographic, clinical and biomarker information and survival was investigated with the Cox model.ResultsFifty-three patients were included in the study. A weak positive correlation was observed between the PD-L1 and vimentin (ρ=0.41, P=0.003). Patients with PD-L1 values

Published
2021
Full Text
View/download PDF

2. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Author

Danilo Rocco, Alex Friedlaender, Alfredo Addeo, Diego Signorelli, Alessio Cortellini, Sebastiano Buti, Raffaele Giusti, Marcello Tiseo, Pietro Di Marino, Michele De Tursi, Federica Zoratto, Marco Russano, Marco Filetti, Francesca Rastelli, Rita Chiari, Biagio Ricciuti, Alain Gelibter, Mario Alberto Occhipinti, Giampiero Porzio, Corrado Ficorella, Emilio Bria, Alessandro Morabito, Giuseppe L Banna, Joachim GJV Aerts, Fausto Barbieri, Diego L Cortinovis, Maria R Migliorino, Annamaria Catino, Francesco Passiglia, Mariangela Torniai, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Alessandro Inno, Giovanni Mansueto, Francesco Grossi, Pamela Pizzutilo, Fabrizio Citarella, Luca Cantini, Giada Targato, Olga Nigro, Miriam G Ferrara, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Luigi Della Gravara, Fabrizio Tabbò, Serena Ricciardi, Alessandro De Toma, and Fausto Petrelli

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression.Methods We present the outcomes analysis according to baseline body mass index (BMI) and BMI variation in a large cohort of metastatic NSCLC patients with a PD-L1 expression ≥50%, receiving first line pembrolizumab. We also evaluated a control cohort of metastatic NSCLC patients treated with first line platinum-based chemotherapy. Normal weight was set as control group.Results 962 patients and 426 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. Obese patients had a significantly higher objective response rate (ORR) (OR=1.61 (95% CI: 1.04–2.50)) in the pembrolizumab cohort, while overweight patients had a significantly lower ORR (OR=0.59 (95% CI: 0.37–0.92)) within the chemotherapy cohort. Obese patients had a significantly longer progression-free survival (PFS) (HR=0.61 (95% CI: 0.45–0.82)) in the pembrolizumab cohort. Conversely, they had a significantly shorter PFS in the chemotherapy cohort (HR=1.27 (95% CI: 1.01–1.60)). Obese patients had a significantly longer overall survival (OS) within the pembrolizumab cohort (HR=0.70 (95% CI: 0.49–0.99)), while no significant differences according to baseline BMI were found in the chemotherapy cohort. BMI variation significantly affected ORR, PFS and OS in both the pembrolizumab and the chemotherapy cohorts.Conclusions Baseline obesity is associated to significantly improved ORR, PFS and OS in metastatic NSCLC patients with a PD-L1 expression of ≥50%, receiving first line pembrolizumab, but not among patients treated with chemotherapy. BMI variation is also significantly related to clinical outcomes.

Published
2020
Full Text
View/download PDF

3. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression >= 50% and Their Relationship With Clinical Outcomes

Author

Raffaele Giusti, Giorgia Guaitoli, Mario Occhipinti, Diego Cortinovis, Ornella Cantale, Luca Cantini, Cinzia Baldessari, Alessio Cortellini, Francesco Grossi, Linda Pettoruti, Vincenzo Sforza, Giovanni Mansueto, Francesco Passiglia, Francesca Mazzoni, Lorenza Landi, Alain Gelibter, Melissa Bersanelli, Daniele Santini, Paolo Marchetti, Alessandro Morabito, Alessandro Leonetti, Marianna Tudini, Serena Ricciardi, Fabrizio Citarella, Ettore D'Argento, Francesca Rastelli, Matteo Santoni, Vincenzo Di Noia, Giampiero Porzio, Robert A. Belderbos, Claudia Proto, Simona Scodes, Marianna Macerelli, Marco Filetti, Joachim G.J.V. Aerts, Diego Signorelli, Luigi Della Gravara, Carlo Genova, Danilo Rocco, Lorenzo Antonuzzo, Alessandro Tuzi, Cristina Cecchi, Luca Sala, Corrado Ficorella, Marco De Filippis, Giuseppe Luigi Banna, Alessandro Inno, Mariangela Torniai, Pamela Pizzutilo, Emilio Bria, Maria Giovanna Dal Bello, Domenico Galetta, Federico Cappuzzo, Federica Bertolini, Rossana Berardi, Maria Rita Migliorino, Miriam Grazia Ferrara, Clelia Donisi, Rita Chiari, Alessandro De Toma, Olga Nigro, Michele Ghidini, Annamaria Catino, Alfredo Addeo, Federica Zoratto, Alessandro Follador, Pietro Di Marino, Alex Friedlaender, Marco Russano, Biagio Ricciuti, Katia Cannita, and Pulmonary Medicine

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, PD-L1, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Drug-Related Side Effects and Adverse Reactions, First line, irAEs, NSCLC, Pembrolizumab, Immune checkpoint inhibitors, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Immune system, Antineoplastic Agents, Immunological, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Adverse effect, Lung cancer, Aged, Retrospective Studies, Aged, 80 and over, biology, business.industry, Middle Aged, medicine.disease, Prognosis, Survival Rate, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, biology.protein, Carcinoma, Squamous Cell, Pd l1 expression, Female, business, Follow-Up Studies
Abstract

The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung-cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) expression of ≥ 50%.We previously conducted a multicenter retrospective analysis in patients with treatment-naive metastatic NSCLC and a PD-L1 expression of ≥ 50% receiving first-line pembrolizumab. Here, we report the results of the irAE analysis and the potential correlation between irAEs and clinical outcomes.A total of 1010 patients were included in this analysis; after a 6-week landmark selection, 877 (86.8%) patients were included in the efficacy analysis. Any grade irAEs (P .0001), grade 3/4 irAEs (P = .0025), leading to discontinuation irAEs (P = .0144), multiple-site and single-site irAEs (P .0001), cutaneous irAEs (P = .0001), endocrine irAEs (P = .0227), pulmonary irAEs (P = .0479), and rheumatologic irAEs (P = .0018) were significantly related to a higher objective response rate. Any grade irAEs (P .0001), single-site irAEs (P .0001), multiple-site irAEs (P = .0005), cutaneous irAEs (P = .0042), endocrine irAEs (P .0001), gastrointestinal irAEs (P = .0391), and rheumatologic irAEs (P = .0086) were significantly related to progression-free survival. Any grade irAEs (P .0001), single-site irAEs (P .0001), multiple-site irAEs (P = .0003), cutaneous irAEs (P = .0002), endocrine irAEs (P = .0001), and rheumatologic irAEs (P = .0214) were significantly related to overall survival.This study confirms the feasibility and the safety of first-line, single-agent pembrolizumab, in a large, real-world cohort of patients with NSCLC with PD-L1 expression ≥ 50%. The occurrence of irAEs may be a surrogate of clinical activity and improved outcomes in this setting.

Published
2020

4. Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Author

Alfredo Addeo, Vincenzo Di Noia, Robert A. Belderbos, Francesco Grossi, Joachim G.J.V. Aerts, Giampiero Porzio, Simona Scodes, Raffaele Giusti, Federico Cappuzzo, Giorgia Guaitoli, Diego Signorelli, Lorenzo Antonuzzo, Corrado Ficorella, Alessio Cortellini, Luigi Della Gravara, Alex Friedlaender, Giovanni Mansueto, Sebastiano Buti, Marcello Tiseo, Emilio Bria, Paolo Marchetti, Simona Carnio, Domenico Galetta, Alain Gelibter, Giada Targato, Ornella Cantale, Lorenza Landi, Diego Cortinovis, Maria Giovanna Dal Bello, Alessandro De Toma, Olga Nigro, Russano Marco, Luca Sala, Cinzia Baldessari, Michele De Tursi, Paola Bordi, Mariangela Torniai, Miriam Grazia Ferrara, Vincenzo Sforza, Marco Filetti, Maria Rita Migliorino, Claudia Proto, Giuseppe Luigi Banna, Alessandro Tuzi, Giulio Metro, Daniele Santini, Ettore D'Argento, Erika Rijavec, Stefania Gori, Biagio Ricciuti, Serena Ricciardi, Annamaria Catino, Rossana Berardi, Federica Zoratto, Marianna Macerelli, Paolo Bironzo, Luca Cantini, Fausto Barbieri, Francesca Mazzoni, Rita Chiari, Francesca Rastelli, Alessio Grieco, Alessandro Morabito, Fabrizio Citarella, Matteo Santoni, Carlo Genova, Danilo Rocco, Francesco Passiglia, Marianna Tudini, and Pamela Pizzutilo

Subjects
Oncology, medicine.medical_specialty, business.industry, First line, Pembrolizumab, medicine.disease, Metastasis, Clinical trial, Multicenter study, Internal medicine, Tobacco exposure, medicine, In patient, Pd l1 expression, business
Abstract

BackgroundSingle agent pembrolizumab represents the standard first line option for metastatic non-small-cell-lung-cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%.MethodsWe conducted a multicenter study aimed at evaluating the clinicopathologic correlates of pembrolizumab efficacy in patients with treatment-naïve NSCLC and a PD-L1 TPS ≥ 50%.Results1026 consecutive patients were included. ECOG-PS ≥ 2 (p < 0.0001) and bone metastases (p = 0.0003) were confirmed to be independent predictors of a worse ORR. Former smokers (p = 0.0002), but not current smokers (p = 0.0532) were confirmed to have a significantly prolonged PFS compared to never smokers at multivariate analysis. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a worse PFS. Previous palliative RT was significantly related to a shortened OS (p = 0.0104), while previous non-palliative RT was significantly related to a prolonged OS (p = 0.0033). Former smokers (p = 0.0131), but not current smokers (p = 0.3433) were confirmed to have a significantly prolonged OS compared to never smokers. ECOG-PS (p < 0.0001), bone metastases (p < 0.0001) and liver metastases (p < 0.0001) were also confirmed to be independent predictors of a shortened OS. A PD-L1 expression of ≥ 90%, as assessed by recursive partitioning, was associated with significantly higher ORR (p = 0.0204), and longer and OS (p = 0.0346) at multivariable analysis.Conclusionspembrolizumab was effective in a large cohort of NSCLC patients treated outside of clinical trials. We confirmed that the absence of tobacco exposure, and the presence of bone and liver metastasis are associated with worse clinical outcomes to pembrolizumab. Increasing levels of PD-L1 expression may help identifying a subset of patients who derive a greater benefit from pembrolizumab monotherapy.

Published
2020
Full Text
View/download PDF

5. Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients

Author

Simona Scodes and Federico Cappuzzo

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Antineoplastic Agents, Drug resistance, 03 medical and health sciences, chemistry.chemical_compound, Exon, 0302 clinical medicine, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Immunology and Allergy, Humans, Osimertinib, 030212 general & internal medicine, Epidermal growth factor receptor, Precision Medicine, Lung cancer, Protein Kinase Inhibitors, Quinazolinones, Chemotherapy, Acrylamides, Aniline Compounds, biology, business.industry, Point mutation, Public Health, Environmental and Occupational Health, medicine.disease, Dacomitinib, ErbB Receptors, Treatment Outcome, 030228 respiratory system, chemistry, Mutation, biology.protein, business
Abstract

Introduction: Epidermal growth factor receptor (EGFR) mutations occur in a significant fraction of non-small cell lung cancer (NSCLC) patients. Most common activating mutations are in-frame deletion in exon 19 and point mutation in exon 21. EGFR tyrosine kinase inhibitors (TKIs) represent standard of care of EGFR mutated patients bearing common mutations. Therapy for individuals carrying uncommon mutations, such as G719X, L861Q, S768I, is less defined and few options exist for individuals harboring EGFR exon 20 mutations. In all mutated patients, drug resistance remains the most critical clinical problem and new agents and strategies are under investigation.Areas covered: We have reviewed the current status of NSCLC EGFR mutated treatment by analyzing data from preclinical studies, clinical prospective and retrospective trials in order to analyze current and future options for patients harboring different EGFR mutations.Expert opinion: At the present time, available data demonstrated that osimertinib is the best EGFR-TKI for front-line therapy. Other agents, such as dacomitinib, and new drug combinations, such as regimens including anti-angiogenic agents or chemotherapy, demonstrated to significantly prolong progression-free survival or overall survival, representing potential alternative to osimertinib. Many questions remain opened, including best drug sequencing and needing of new therapeutic approaches extending patient survival and cure rate.

Published
2020

6. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >= 50%: a multicenter study with external validation

Author

Alessio Cortellini, Miriam Grazia Ferrara, Giovanni Mansueto, Sebastiano Buti, Francesco Passiglia, Francesco Grossi, Luigi Della Gravara, Alain Gelibter, Lorenza Landi, Annamaria Catino, Simona Scodes, Francesca Rastelli, Carlo Genova, Danilo Rocco, Mario Occhipinti, Mariangela Torniai, Federica Zoratto, Pamela Pizzutilo, Diego Cortinovis, Pietro Di Marino, Fausto Petrelli, Vincenzo Di Noia, Alfredo Addeo, Giampiero Porzio, Rita Chiari, Serena Ricciardi, Michele De Tursi, Alex Friedlaender, Marcello Tiseo, Raffaele Giusti, Giorgia Guaitoli, Giuseppe Luigi Banna, Emilio Bria, Maria Rita Migliorino, Joachim G.J.V. Aerts, Marco Filetti, Alessandro De Toma, Diego Signorelli, Giada Targato, Corrado Ficorella, Olga Nigro, Fausto Barbieri, Marco Russano, Biagio Ricciuti, Luca Cantini, Francesca Mazzoni, Fabrizio Tabbò, Alessandro Morabito, Fabrizio Citarella, Alessandro Inno, and Pulmonary Medicine

Subjects
0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, First line, medicine.medical_treatment, Immunology, Pembrolizumab, Overweight, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, immunotherapy, oncology, Internal medicine, Carcinoma, Non-Small-Cell Lung, Immunology and Allergy, Medicine, Humans, Obesity, RC254-282, Aged, Pharmacology, Aged, 80 and over, Clinical/Translational Cancer Immunotherapy, Chemotherapy, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, medicine.disease, 030104 developmental biology, Multicenter study, 030220 oncology & carcinogenesis, Cohort, Molecular Medicine, Female, medicine.symptom, business, Body mass index
Abstract

BackgroundThe association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression.MethodsWe present the outcomes analysis according to baseline body mass index (BMI) and BMI variation in a large cohort of metastatic NSCLC patients with a PD-L1 expression ≥50%, receiving first line pembrolizumab. We also evaluated a control cohort of metastatic NSCLC patients treated with first line platinum-based chemotherapy. Normal weight was set as control group.Results962 patients and 426 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. Obese patients had a significantly higher objective response rate (ORR) (OR=1.61 (95% CI: 1.04–2.50)) in the pembrolizumab cohort, while overweight patients had a significantly lower ORR (OR=0.59 (95% CI: 0.37–0.92)) within the chemotherapy cohort. Obese patients had a significantly longer progression-free survival (PFS) (HR=0.61 (95% CI: 0.45–0.82)) in the pembrolizumab cohort. Conversely, they had a significantly shorter PFS in the chemotherapy cohort (HR=1.27 (95% CI: 1.01–1.60)). Obese patients had a significantly longer overall survival (OS) within the pembrolizumab cohort (HR=0.70 (95% CI: 0.49–0.99)), while no significant differences according to baseline BMI were found in the chemotherapy cohort. BMI variation significantly affected ORR, PFS and OS in both the pembrolizumab and the chemotherapy cohorts.ConclusionsBaseline obesity is associated to significantly improved ORR, PFS and OS in metastatic NSCLC patients with a PD-L1 expression of ≥50%, receiving first line pembrolizumab, but not among patients treated with chemotherapy. BMI variation is also significantly related to clinical outcomes.

Published
2020

7. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Author

Giovanni Mansueto, Lorenza Landi, Francesco Grossi, Cinzia Baldessari, Michele De Tursi, Alessio Cortellini, Vincenzo Sforza, Alain Gelibter, Raffaele Giusti, Biagio Ricciuti, Giuseppe Luigi Banna, Daniele Santini, Giorgia Guaitoli, Joachim G.J.V. Aerts, Russano Marco, Rita Chiari, Ornella Cantale, Luca Sala, Mariangela Torniai, Stefania Gori, Claudia Proto, Luigi Della Gravara, Diego Signorelli, Lorenzo Antonuzzo, Emilio Bria, Francesco Passiglia, Serena Ricciardi, Luca Cantini, Corrado Ficorella, Simona Carnio, Annamaria Catino, Paola Bordi, Vincenzo Di Noia, Miriam Grazia Ferrara, Maria Giovanna Dal Bello, Domenico Galetta, Sebastiano Buti, Federica Zoratto, Giampiero Porzio, Marianna Tudini, Paolo Marchetti, Diego Cortinovis, Erika Rijavec, Matteo Santoni, Carlo Genova, Danilo Rocco, Alex Friedlaender, Robert A. Belderbos, Ettore D'Argento, Simona Scodes, Pamela Pizzutilo, Marcello Tiseo, Alfredo Addeo, Marianna Macerelli, Rossana Berardi, Giada Targato, Federico Cappuzzo, Francesca Mazzoni, Alessandro Morabito, Fabrizio Citarella, Maria Rita Migliorino, Alessandro De Toma, Olga Nigro, Paolo Bironzo, Fausto Barbieri, Marco Filetti, Alessandro Tuzi, Giulio Metro, Francesca Rastelli, Alessio Grieco, and Pulmonary Medicine

Subjects
Oncology, Cancer Research, medicine.medical_treatment, Bone metastases, Liver metastases, PD-L1, Performance status, Radiotherapy, Smoking status, Pembrolizumab, carcinoma, Metastasis, Antineoplastic Agents, Immunological, bone metastases, Carcinoma, Non-Small-Cell Lung, middle aged, antineoplastic agents, Immunology and Allergy, antibodies, humans, humanized, adult, liver metastases, pd-l1, performance status, radiotherapy, smoking status, aged, antibodies, monoclonal, immunological, b7-h1 antigen, non-small-cell lung, female, lung neoplasms, male, progression-free survival, retrospective studies, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Progression-Free Survival, Retrospective Studies, medicine.medical_specialty, Immunology, monoclonal, Antibodies, Monoclonal, Humanized, Internal medicine, medicine, Progression-free survival, Lung cancer, business.industry, Retrospective cohort study, medicine.disease, Radiation therapy, business
Abstract

Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. We conducted a multicenter retrospective study aimed at evaluating the clinicopathologic correlates of pembrolizumab effectiveness in patients with treatment-naive NSCLC and a PD-L1 expression of ≥ 50%. One thousand and twenty-six consecutive patients were included. The objective response rate (ORR) was 44.5% (95% CI 40.2–49.1), while the median progression free survival (PFS) and overall survival (OS) were 7.9 months (95% CI 6.9–9.5; 599 events) and 17.2 months (95% CI 15.3–22.3; 598 censored patients), respectively. ECOG-PS ≥ 2 (p

Published
2020

8. Prognostic and Predictive Role of Neutrophil to lymphocyte Ratio in Second Line Immunotherapy of Non-small Cell Lung Cancer

Author

Martina Mandarano, Michela Spreafico, M. D'Arcangelo, Antonello Menghi, Marco Montanari, Dora Caruso, Guido Bellezza, Alessio Gili, Sara Pini, Giulio Rossi, Simona Scodes, Federica Gazzaneo, Giorgio Papiani, Valentina Mazza, Chiara Bennati, and Stefano Tamberi

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, fungi, Retrospective cohort study, Immunotherapy, medicine.disease, Systemic inflammation, Internal medicine, medicine, Immunohistochemistry, Biomarker (medicine), Neutrophil to lymphocyte ratio, Nivolumab, medicine.symptom, Lung cancer, business
Abstract

Background: Programmed death-ligand 1 (PD-L1) expression at immunohistochemistry is the only approved, but still unsatisfactory, biomarker for immunotherapy in Non-Small Cell Lung Cancer (NSCLC). Neutrophil to Lymphocyte ratio (NLR) is a surrogate of systemic inflammation and could correlate with outcome to immunotherapy. This retrospective study (NCT03816657) explored the role of NLR in predicting benefit to nivolumab and susceptibility to hyperprogression (HPD). Methods: PD-L1, baseline and on-therapy NLR values were available in 173NSCLC patients receiving nivolumab. PD-L1 positivity was defined as expression on ≥1% of tumor cells; NLR was dichotomized in high (≥5) or low (

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results